Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 5, 2024Annals of Clinical and Translational NeurologyOpen Access

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

View Full Paper
Ask AI
Bookmark
Share

Authors

PIPietro IaffaldanoUniversity of Bari Aldo MoroGLGiuseppe LucisanoCenter for Outcomes Research and Clinical EpidemiologyTGTommaso GuerraUniversity of Bari Aldo Moro

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Iaffaldano et al. (2024) studied this question.

synapsesocial.com/papers/68e613bcb6db6435875a63c7https://doi.org/10.1002/acn3.52118
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study2026
  2. 2Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study2012 · 43 citations
  3. 3Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis2025
  4. 4Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis2024 · 4 citations
  5. 5Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis2025